Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05095922
Other study ID # HMP2008007p
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 28, 2023
Est. completion date May 30, 2024

Study information

Verified date December 2023
Source Affiliated Hospital of Nantong University
Contact Xinlei Wang, doctor
Phone 086+13814707820
Email rubi221@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study mainly investigates the therapeutic effect of Heart-Protecting Musk Pill (HMP) on patients with diabetic microangiopathy. According to the indicators of diabetic nephropathy (DN), diabetic retinopathy (DR), oxidative stress and inflammatory factor in patients with diabetic microvascular disease after using HMP, the investigators aim to evaluate the effect of HMP on diabetic microangiopathy, oxidative stress and inflammation.


Description:

Diabetes can lead to many diseases as diabetic macrovascular and microvascular complications which result in high disability and mortality rate, thereby seriously affecting the quality of life and life expectancy of diabetic patients. It not only aggravates the family burden of patients, but also becomes the main burden of public health services around the world. Diabetic nephropathy (DN) and diabetic retinopathy (DR) are more serious in diabetic microangiopathy. The glomerulus and retina have the similar tissue structure and physiological function. Therefore, when they are exposured to the same risk factors can lead to microcirculation damage of kidney and retina. DN and DR have similar pathogenesis and development processes. Although the susceptibility genes and cytokines of DN and DR are different, the two can still be predictors of each other and they often coexist in diabetic patients. At present, there are few drugs with definite curative effect on the treatment of diabetic microangiopathy, therefore the treatment of diabetic microangiopathy is an aspect that urgently needs a breakthrough in chronic complications of diabetes. Traditional Chinese medicine has a history of preventing and treating diabetes for thousands of years. For the treatment of chronic complications of diabetes by Chinese medicine, although there are not many Chinese medicines that have obtained curative effects, it has indeed accumulated rich experience in the process of research and clinical treatment that Western medicine could not obtain. Therefore, seeking Chinese medicine to effectively treat diabetic microvascular disease has become a direction worthy of attention and research. Heart-Protecting Musk Pill (HMP) is a commonly used drug in clinical treatment, which comprises seven medicinal substances: Radix Ginseng, Venenum Bufonis, Styrax, Calculus Bovis Artifactus, Cortex Cinnamomi, Borneolum Syntheticum and Artificial Moschus. HMP is a traditional Chinese medicinal compound, which has been effectively used for treating coronary heart disease (CHD) and diabetic macrovascular disease. However, studies on Chinese medicines that are partially similar to HMP have shown that they can improve diabetic retinopathy. Therefore, the study of the efficacy of HMP on diabetic microangiopathy is extremely valuable. Previous researches have shown that HMP owns the effects of reducing oxidative stress, improving inflammation, anti-plateleting aggregation, promoting plasmin activity, and improving hemodynamics. It is possible that HMP can delay or improve the occurrence and development of diabetic microangiopathy through the above effects and even other unclear mechanisms. At present, the drugs used for clinical treatment of type 2 diabetic microangiopathy are limited. Although the pharmacological indications of HMP can be used to deal with the pathogenesis of diabetic microvascular complications, there is still no clinical study of HMP for the treatment of diabetic microvascular complications. Therefore, this study compared the differences in indicators related to diabetic nephropathy, diabetic retinopathy, oxidative stress, and inflammatory factors between the control group and the HMP group before and after treatment to clarify the therapeutic effect of HMP on diabetic microangiopaemia.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date May 30, 2024
Est. primary completion date May 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of Diabetes mellitus - Prescribed for Valsartan Capsules and Calcium Dobesilate Capsules Exclusion Criteria: - Type 1 diabetes mellitus - Secondary diabetes - Malignant tumors - Active infection - Acute diabetic complications - Macrovascular complications - Mental illness - Intellectual disability - Impaired heart function - Impaired liver function - Impaired kidney function

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Heart-Protecting Musk Pill
Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
Valsartan Capsules
Valsartan Capsules(capsule, 80mg, once a day, 3 months)
Calcium Dobesilate Capsules
Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)

Locations

Country Name City State
China Affiliated Hospital of Nantong University Nantong Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Affiliated Hospital of Nantong University

Country where clinical trial is conducted

China, 

References & Publications (5)

Deng X, Sun L, Lai X, Xiang L, Li Q, Zhang W, Zhang L, Sun S. Tea Polypeptide Ameliorates Diabetic Nephropathy through RAGE and NF-kappaB Signaling Pathway in Type 2 Diabetes Mice. J Agric Food Chem. 2018 Nov 14;66(45):11957-11967. doi: 10.1021/acs.jafc.8b04819. Epub 2018 Nov 1. — View Citation

Fan X, Shi M, Wang Y, Liang Q, Luo G. Transcriptional profiling analysis of HMP-treated rats with experimentally induced myocardial infarction. J Ethnopharmacol. 2011 Sep 1;137(1):199-204. doi: 10.1016/j.jep.2011.05.010. Epub 2011 May 13. — View Citation

Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010 Apr 30;106(8):1319-31. doi: 10.1161/CIRCRESAHA.110.217117. — View Citation

Lu L, Qin Y, Chen C, Zhang X, Xu X, Lv C, Wan X, Ruan W, Guo X. The atheroprotective roles of heart-protecting musk pills against atherosclerosis development in apolipoprotein E-deficient mice. Ann Transl Med. 2019 Dec;7(23):714. doi: 10.21037/atm.2019.12.22. — View Citation

Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, Gregg EW, Albright AL, Klein BE, Klein R. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010 Aug 11;304(6):649-56. doi: 10.1001/jama.2010.1111. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of biochemical Indicators Total cholesterol(TC), Triglycerides(TG), High-density lipoprotein cholesterol(HDL-C), Low-density lipoprotein cholesterol(LDL-C), Fasting blood glucose(FBG), Blood urea nitrogen(BUN) Change from Baseline TC, TG, HDL-C, LDL-C, FBG, BUN at 3 months
Primary Concentration of Glycosylated hemoglobin Glycosylated hemoglobin(HbA1c) Change from Baseline HbA1c at 3 months
Primary Concentration of hypersensitive-c-reactive-protein and Cystatin C hypersensitive-c-reactive-protein(hs-CRP), Cystatin C(CysC) Change from Baseline hs-CRP and CysC at 3 months
Primary Concentration of Serum creatinine Serum creatinine(Scr) Change from Baseline Scr at 3 months
Primary Rate of estimated Glomerular Filtration estimated Glomerular Filtration Rate(eGFR) Change from Baseline eGFR at 3 months
Primary Ratio of Urinary albumin to creatinine Urinary albumin to creatinine Ratio(UACR) Change from Baseline UACR at 3 months
Primary Concentration of Serum fatty acid binding protein 4 Serum fatty acid binding protein 4(FABP4) Change from Baseline FABP4 at 3 months
Primary Indicators of diabetic retinopathy The vision and fundus photography will be checked by an ophthalmologist to determine the effect. Change from Baseline effect at 3 months
Primary Concentration of inflammation indicator Tumor Necrosis Factor-a(TNF-a) Change from Baseline TNF-a at 3 months
Primary Concentration of inflammation indicator Vascular Endothelial Growth Factor(VEGF) Change from Baseline VEGF at 3 months
Primary Concentration of inflammation indicator CC chemokine ligand 3(CCL3) Change from Baseline CCL3 at 3 months
Primary Concentration of Oxidative stress indicator Superoxide dismutase(SOD) Change from Baseline SOD at 3 months
Primary Concentration of Oxidative stress indicator Glutathione peroxidase(GSH-Px) Change from Baseline GSH-Px at 3 months
Primary Concentration of Oxidative stress indicator Reactive oxygen species(ROS) Change from Baseline ROS at 3 months
Primary Clinical characteristics Height, Waistline Change from Baseline Height, Waistline at 3 months
Primary Clinical characteristic Weight Change from Baseline Weight at 3 months
Primary Blood pressure Systolic Blood Pressure(SBP), Diastolic Blood Pressure(DBP) Change from Baseline SBP, DBP at 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2